Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Immunology · Complement Factor I Deficiency

Protecting Your Health: Treatment and Monitoring

At a Glance

CFI deficiency is managed by preventing serious infections with recommended vaccines and often daily antibiotics, while monitoring kidney, eye, and blood pressure health. Complement inhibitors may be used by specialists if CFI-related kidney disease develops.

Managing Complement Factor I (CFI) deficiency is a lifelong commitment to prevention. Because your immune system is missing its natural regulator, the goal of treatment is to build a “protective shell” around you or your child. This involves a combination of medical interventions and routine monitoring to catch potential complications before they become severe [1][2].

The Shield: Vaccinations and Antibiotics

The most critical part of your daily defense is preventing infections from encapsulated bacteria.

  • Vaccination Strategy: Standard care follows jurisdictional high-risk schedules (such as ACIP in the US) for complement-deficient patients, which vary by age and country. This includes vaccines against Meningococcal (both ACWY and B types), Pneumococcal, and Haemophilus influenzae type b (Hib), as well as routine immunizations like seasonal influenza and COVID-19 [3][1]. It is important to note that while vaccines are vital, they may not provide 100% protection in complement-deficient individuals, making other measures necessary, and checking antibody titers does not routinely replace the recommended schedule [4][5].
  • Prophylactic Antibiotics: Most specialists recommend a daily, low-dose “preventive” antibiotic to stop bacteria from multiplying in the blood [1][6]. While the specific drug and dose are tailored to each patient, this acts as a second layer of security alongside vaccines. However, prophylactic antibiotics do not treat breakthrough infections and do not make a fever safe to observe at home [2].
  • A Note on Immunoglobulins: Unlike some other immune deficiencies, Immunoglobulin Replacement Therapy (IgRT) is not a standard treatment for CFI deficiency alone [7]. It is generally only used if blood tests show that you also have a separate problem making antibodies, which is not typical for most CFI-deficient patients [8][2].

Treating Kidney Complications

If the “runaway” complement system begins to damage the kidneys, specialized medications called complement inhibitors may be used. These drugs are designed to manually shut down the part of the immune system that Factor I usually controls, though their use in CFI-associated kidney disease may be off-label and requires specialist judgment [9].

  • For aHUS: Doctors often use C5 inhibitors like eculizumab or ravulizumab [9]. These medications have been shown in some CFI-deficient patients to help stop the destruction of red blood cells and, in some cases, improve kidney function [10][11].
  • For C3 Glomerulopathy (C3G): Newer “proximal” inhibitors, such as iptacopan (approved for adults) or pegcetacoplan (approved for adults and adolescents depending on jurisdiction), may be used to target the immune system earlier in the process [12][13]. These drugs aim to reduce the amount of protein leaking into the urine and protect long-term kidney health [14][12].
  • Critical Warning: C5 inhibitors substantially increase the risk of meningococcal infection, requiring strict adherence to specialized vaccination and prophylactic antibiotic protocols, though urgent treatment for a crisis should not be delayed solely to complete vaccines.

Routine Monitoring: Your Early Warning System

Because CFI deficiency can affect multiple organs over time, regular “check-ups” are essential even when you feel perfectly healthy.

  1. Renal (Kidney) Monitoring: You should have an individualized schedule of testing, including a urinalysis (to check for blood or protein) and blood tests for creatinine (to measure how well the kidneys are filtering) as determined by your nephrologist [15][16].
  2. Ophthalmological (Eye) Monitoring: Because of the link to macular degeneration, a discussion with an ophthalmologist about baseline and periodic eye exams is recommended [17]. This should include retinal photography or Optical Coherence Tomography (OCT)—a non-invasive imaging test that can see thinning or deposits in the retina long before they affect your vision [18][19].
  3. Blood Pressure: Regular monitoring of blood pressure is a simple but effective way to screen for early kidney stress [15].

By staying consistent with these preventive steps and monitoring, the goal is to shift the focus from “crisis management” to “health maintenance,” allowing for a more predictable and active life.

Common questions in this guide

Which vaccines are recommended for someone with CFI deficiency?
High-risk vaccination schedules for complement deficiency generally include meningococcal, pneumococcal, Haemophilus influenzae type b, influenza, and COVID-19 vaccines. Timing and booster needs depend on age and location, and vaccines may not fully prevent infection, so fever still needs prompt medical assessment.
Are daily antibiotics usually needed for CFI deficiency?
Many specialists recommend a daily low-dose preventive antibiotic to reduce the risk of serious bacterial infections. It does not treat a breakthrough infection or make a fever safe to watch at home, so follow your care team’s plan if illness develops.
Is immunoglobulin replacement used to treat CFI deficiency?
Immunoglobulin replacement is not usually needed for CFI deficiency alone because antibody production is often otherwise intact. It may be considered if testing finds a separate antibody deficiency, so clinicians may check antibody levels before recommending it.
What treatments may be used if CFI deficiency causes kidney disease?
Specialists may use complement inhibitors when CFI deficiency is associated with atypical hemolytic uremic syndrome or C3 glomerulopathy. Eculizumab or ravulizumab may be used for some patients with atypical hemolytic uremic syndrome, while iptacopan or pegcetacoplan may be considered for appropriate patients with C3 glomerulopathy, depending on age and local approvals. These medicines require careful infection-prevention planning.
How are kidney and eye problems monitored in CFI deficiency?
Kidney follow-up may include urine testing for blood or protein, creatinine blood tests, and regular blood-pressure checks on an individualized schedule. Eye follow-up may include baseline and periodic retinal photography or optical coherence tomography to detect retinal changes before they affect vision.
What should I do if I develop a fever while taking preventive antibiotics?
A fever can signal a serious infection and should be assessed promptly even when preventive antibiotics are being taken. Do not rely on the daily antibiotic or wait at home without medical advice; use the urgent-care plan provided by your care team.

Get notified when new evidence is published on Immunodeficiency with factor I anomaly.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (19)
  1. 1

    Inherited Classical and Alternative Pathway Complement Deficiencies in Children: A Single Center Experience.

    Genel F, Erdem SB, Gülez N, et al.

    Iranian journal of immunology : IJI 2018; (15(4)):309-320 doi:10.22034/IJI.2018.39400.

    PMID: 30593745
  2. 2

    Early Versus Late Diagnosis of Complement Factor I Deficiency: Clinical Consequences Illustrated in Two Families with Novel Homozygous CFI Mutations.

    Franco-Jarava C, Álvarez de la Campa E, Solanich X, et al.

    Journal of clinical immunology 2017; (37(8)):781-789 doi:10.1007/s10875-017-0447-x.

    PMID: 28942469
  3. 3

    Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.

    Mbaeyi SA, Bozio CH, Duffy J, et al.

    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports 2020; (69(9)):1-41 doi:10.15585/mmwr.rr6909a1.

    PMID: 33417592
  4. 4

    Multi-component meningococcal serogroup B (MenB)-4C vaccine induces effective opsonophagocytic killing in children with a complement deficiency.

    van den Broek B, van Els CACM, Kuipers B, et al.

    Clinical and experimental immunology 2019; (198(3)):381-389 doi:10.1111/cei.13368.

    PMID: 31487400
  5. 5

    Immunogenicity and safety of meningococcal vaccines, MenACWY-CRM and 4CMenB, in groups at increased risk for meningococcal disease.

    Bobde S, Bhusal C, Cosgrove CA, Sohn WY

    Expert review of vaccines 2025; (24(1)):656-667 doi:10.1080/14760584.2025.2536079.

    PMID: 40684304
  6. 6

    Clinical laboratory standard capillary protein electrophoresis alerted of a low C3 state and lead to the identification of a Factor I deficiency due to a novel homozygous mutation.

    Franco-Jarava C, Colobran R, Mestre-Torres J, et al.

    Immunology letters 2016; (174()):19-22.

    PMID: 27091480
  7. 7

    Complete Complement Factor I (CFI) deficiency: a systematic review of forty-nine patients including three novel cases.

    Rajabi E, Kheirabadi MC, Olyaei NA, et al.

    BMC immunology 2025; (26(1)):54 doi:10.1186/s12865-025-00739-y.

    PMID: 40713518
  8. 8

    Disseminated gonococcal infection secondary to a rare homozygous mutation resulting in complement factor I deficiency.

    Almpani M, Welch G, Vanderleeden E, et al.

    Journal of human immunity 2025; (1(3)):e20250088 doi:10.70962/jhi.20250088.

    PMID: 41607490
  9. 9

    Advancements in complement inhibition for PNH and primary complement-mediated thrombotic microangiopathy.

    Padilla Kelley T, King H, Malhotra A, et al.

    Blood advances 2025; (9(15)):3937-3945 doi:10.1182/bloodadvances.2024015777.

    PMID: 40354320
  10. 10

    [Hemolytic kidney failure and transient ischemic attack in a 32-year-old female].

    Anders R, Grohmann M, Lindner TH, et al.

    Der Internist 2016; (57(10)):1022-1028 doi:10.1007/s00108-016-0092-0.

    PMID: 27357251
  11. 11

    Atypical hemolytic-uremic syndrome due to complement factor I mutation.

    Almalki AH, Sadagah LF, Qureshi M, et al.

    World journal of nephrology 2017; (6(6)):243-250 doi:10.5527/wjn.v6.i6.243.

    PMID: 29226095
  12. 12

    Complement-targeted therapies for C3 glomerulopathy and atypical hemolytic uremic syndrome: a time-limited rapid systematic review with narrative synthesis.

    Wu Q, Yu Z, Wu Z, et al.

    Frontiers in medicine 2026; (13()):1867718 doi:10.3389/fmed.2026.1867718.

    PMID: 42621905
  13. 13

    Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons.

    Dixon BP, Bomback AS, Rich C, et al.

    Advances in therapy 2026; (43(8)):3385-3402 doi:10.1007/s12325-026-03614-3.

    PMID: 42138781
  14. 14

    Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study.

    Kavanagh D, Bomback AS, Vivarelli M, et al.

    Lancet (London, England) 2025; (406(10512)):1587-1598 doi:10.1016/S0140-6736(25)01148-1.

    PMID: 41016405
  15. 15

    Long-term outcome of pediatric anti-complement factor H antibody-associated atypical hemolytic uremic syndrome receiving abbreviated plasma exchange: a retrospective study from a single center.

    Vallabhaneni P, Dawman L, Rawat A, et al.

    Journal of nephrology 2026; doi:10.1093/joneph/aajag189.

    PMID: 42678244
  16. 16

    Complement Factor I Gene Variant in an Atypical Hemolytic Uremic Syndrome Triggered by Hypereosinophilia Syndrome.

    Banjongjit A, Kittanamongkolchai W, Kanjanabuch T

    Nephron 2023; (147(11)):701-706 doi:10.1159/000531879.

    PMID: 37611541
  17. 17

    Complement factor I: Regulatory nexus, driver of immunopathology, and therapeutic.

    Hallam TM, Sharp SJ, Andreadi A, Kavanagh D

    Immunobiology 2023; (228(5)):152410 doi:10.1016/j.imbio.2023.152410.

    PMID: 37478687
  18. 18

    Rare Dysfunctional Complement Factor I Genetic Variants and Progression to Advanced Age-Related Macular Degeneration.

    Seddon JM, Rosner B, De D, et al.

    Ophthalmology science 2023; (3(2)):100265 doi:10.1016/j.xops.2022.100265.

    PMID: 36909148
  19. 19

    Geographic Atrophy in Patients with Age-Related Macular Degeneration Is Associated with Rare Variants in Complement Factor H and Complement Factor I.

    de Breuk A, de Jong S, Bakker B, et al.

    Ophthalmology science 2026; (6(6)):101171 doi:10.1016/j.xops.2026.101171.

    PMID: 42222588

This page is for informational purposes only and does not constitute medical advice. Your immunology, nephrology, and ophthalmology teams should tailor vaccines, antibiotics, kidney treatments, and monitoring to your situation.

Guide contents Immunodeficiency with factor I anomaly
Research & Literature
04 Beyond Infection 06 Building Your Care Team and Preparing for Visits